


Alazraki, Melly, The 10 Biggest-Selling Drugs that are about to Lose Their Patents, DailyFinance, February 27, 2011.


Bibliography


Bessen, James/Maskin, Eric, Sequential Innovation, Patents, and Imitation, 40 RAND J. Econ. 611 (2009).


Brandi-Dohrn, Matthias, Der zu weite Patentanspruch, GRUR Int 1995, 541.


Bublak, Wolfgang/Coehn, Markus., Offenbarungsgehalt der Vorveröffentlichung einer chemischen Strukturformel (Disclosure in the Prior Publication of a Chemical Structural Formula), GRUR 2009, 382.


Bibliography


Chisum, Donald S., Chisum on Patents, Newark: LexisNexis (2012).


Crouch, Dennis D., Nil: the Value of Patents in a Major Crisis such as an Influenza Pandemic, 39 Seton Hall L. Rev. 1125 (2009).


Dasgupta, Partha, Patents, Priority and Imitation or the Economics of Races and Waiting Games, 98 Econ. J. 66 (1988).


Bibliography


Eisenberg, Rebecca S., Patents and the Progress of Science: Exclusive Rights and Experimental Use, 56 U. Chi. L. Rev. 1017 (1989).


Gaudillière, Jean-Paul, Professional or Industrial Order? Patents, Biological Drugs, and Pharmaceutical Capitalism in Early Twentieth Century Germany, 24 Hist. & Tech. 107 (2008).
Bibliography


Bibliography


Jack, Andrew, Drugs Groups Forced to Put Squeeze on R&D, Fin. Times, October 17, 2011.


Jacob, Robin, Some Recent Cases of Significance in the UK, IIC 1997, 880.


Bibliography


Kling, Jim, From Hypertension to Angina to Viagra, 1 Modern Drug Discov. 31 (1998).


Kola, Ismail/Landis, John, Can the pharmaceutical industry reduce attrition rates?, 3 Nat. Rev. Drug Discov. 711 (2004).


Lichtenberg, Frank R., Are The Benefits Of Newer Drugs Worth Their Cost? Evidence From The 1996 MEPS-The newer the drug in use, the less spending on nondrug items, 20 Health Affair. 241 (2001).


Mansell, Peter, Who is afraid of the patent cliff? 1 Scrip Executive Briefing 1 (2008).


Bibliography


Nastelski, Karl, Product Protection for Chemical Inventions in Germany, IIC 1972, 267.


Pagenberg, Jochen, Beweisanzeichen auf dem Prüfstand Für eine objektive Prüfung auf erfinderische Tätigkeit, GRUR Int 1986, 83.


Bibliography


Privitera, Michael, Large Clinical Trials in Epilepsy: Funding by the NIH versus Pharmaceutical Industry, 68 Epilepsy Res. 52 (2006).


Roberts, Tim, Broad Claims for Biotechnological Inventions, EIPR, 1994, 371.


Rose, Carol M., Possession as the Origin of Property, 52 U. Chi. L. Rev. 73 (1985).


Sachs, George/Shin, Jai M./Howden, Collin W., Review Article: the Clinical Pharmacology of Proton Pump Inhibitors, 23 (Suppl. 2) Aliment Pharm. Ther. 2 (2006).


Bibliography


Shadowen, Steve D./Leffler, Keith B./Luken, Joseph T., Bringing Market Discipline to Pharmaceutical Product Reformulations, IIC 2011, 698.


Smith, Austin, 'No' to Ban on Stem-Cell Patents, 472 Nature 418 (2011).


Steele, Henry, Monopoly and Competition in the Ethical Drugs Market, 5 J. Law Econ. 131 (1962).


Bibliography


Teschemacher, Rudolf, Enlarged Board of Appeal of the EPO Restores Legal Certainty for Divisional Applications – Established Practice Confirmed, IIC 2007, 703.


Tilmann, Winfried, Validity of Selective Product Claims – Venice Conferences III and V, Lundbeck and Olanzapine, IIC 2010, 149.


Bibliography


Vivian, Michael F., Novelty and Selection Inventions, IIC 1989, 303.


Vossius, Corinna/Vossius, Tilman/Vossius, Volker, Der Terfenadin-Verletzungsstreit; zum Standard der Neuheitsprüfung, GRUR 1994, 472.


OTHER SOURCES


FDA, Drugs@FDA Glossary of Terms, available at: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm100100.htm

Bibliography


